Rationales and uncertainties for aspirin use in COVID-19: a narrative review
Open Access
- 20 April 2021
- journal article
- review article
- Published by BMJ in Family Medicine and Community Health
- Vol. 9 (2) , e000741
Abstract
Objectives To review the pathophysiology of COVID-19 disease, potential aspirin targets on this pathogenesis and the potential role of aspirin in patients with COVID-19. Design Narrative review. Setting The online databases PubMed, OVID Medline and Cochrane Library were searched using relevant headlines from 1 January 2016 to 1 January 2021. International guidelines from relevant societies, journals and forums were also assessed for relevance. Participants Not applicable. Results A review of the selected literature revealed that clinical deterioration in COVID-19 is attributed to the interplay between endothelial dysfunction, coagulopathy and dysregulated inflammation. Aspirin has anti-inflammatory effects, antiplatelet aggregation, anticoagulant properties as well as pleiotropic effects on endothelial function. During the COVID-19 pandemic, low-dose aspirin is used effectively in secondary prevention of atherosclerotic cardiovascular disease, prevention of venous thromboembolism after total hip or knee replacement, prevention of pre-eclampsia and postdischarge treatment for multisystem inflammatory syndrome in children. Prehospital low-dose aspirin therapy may reduce the risk of intensive care unit admission and mechanical ventilation in hospitalised patients with COVID-19, whereas aspirin association with mortality is still debatable. Conclusion The authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40–70 years who are at high atherosclerotic cardiovascular disease risk, or an intermediate risk with a risk-enhancer and have a low risk of bleeding. Aspirin’s protective roles in COVID-19 associated with acute lung injury, vascular thrombosis without previous cardiovascular disease and mortality need further randomised controlled trials to establish causal conclusions.Keywords
This publication has 58 references indexed in Scilit:
- ACOGObstetrics & Gynecology, 2019
- Risk of stroke associated with use of nonsteroidal anti‐inflammatory drugs during acute respiratory infection episodePharmacoepidemiology and Drug Safety, 2018
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysisCritical Care, 2018
- Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover StudyThe Journal of Infectious Diseases, 2017
- Effects of Aspirin on Endothelial Function and HypertensionCurrent Hypertension Reports, 2016
- Antiviral activity of aspirin against RNA viruses of the respiratory tract—an in vitro studyInfluenza and Other Respiratory Viruses, 2016
- Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2016
- Aspirin as a potential treatment in sepsis or acute respiratory distress syndromeCritical Care, 2015
- New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolismTherapeutics and Clinical Risk Management, 2015
- Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2014